Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy

BackgroundWhat currently appears to be irreversible axonal loss in normal appearing white matter, measured by proton magnetic resonance spectroscopy is of great interest in the study of Multiple Sclerosis. Our aim is to determine the axonal damage in normal appearing white matter measured by magnetic resonance spectroscopy and to correlate this with the functional disability measured by Multiple Sclerosis Functional Composite scale, Neurological Rating Scale, Ambulation Index scale, and Expanded Disability Scale Score.MethodsThirty one patients (9 male and 22 female) with relapsing remitting Multiple Sclerosis and a Kurtzke Expanded Disability Scale Score of 0–5.5 were recruited from four hospitals in Andalusia, Spain and included in the study. Magnetic resonance spectroscopy scans and neurological disability assessments were performed the same day.ResultsA statistically significant correlation was found (r = -0.38 p < 0.05) between disability (measured by Expanded Disability Scale Score) and N-Acetyl Aspartate (NAA/Cr ratio) levels in normal appearing white matter in these patients. No correlation was found between the NAA/Cr ratio and disability measured by any of the other disability assessment scales.ConclusionsThere is correlation between disability (measured by Expanded Disability Scale Score) and the NAA/Cr ratio in normal appearing white matter. The lack of correlation between the NAA/Cr ratio and the Multiple Sclerosis Functional Composite score indicates that the Multiple Sclerosis Functional Composite is not able to measure irreversible disability and would be more useful as a marker in stages where axonal damage is not a predominant factor.

[1]  R. Tarducci,et al.  1H-MRS in patients with multiple sclerosis undergoing treatment with interferon β-1a: results of a preliminary study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[2]  Ponnada A. Narayana,et al.  Proton magnetic resonance spectroscopy in multiple sclerosis , 1990, Neurology.

[3]  W. Mcdonald,et al.  The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.

[4]  R H Edwards,et al.  Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the "invisible" lesion load. , 1994, Magnetic resonance imaging.

[5]  S. Waxman.  Demyelinating diseases--new pathological insights, new therapeutic targets. , 1998, The New England journal of medicine.

[6]  W. Mcdonald.  RACHELLE FISHMAN-MATTHEW MOORE LECTURE: The Pathological and Clinical Dynamics of Multiple Sclerosis , 1994, Journal of neuropathology and experimental neurology.

[7]  P M Matthews,et al.  Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.

[8]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[9]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[10]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[11]  M. Horsfield,et al.  A conventional and magnetization transfer MRI study of the cervical cord in patients with MS , 2000, Neurology.

[12]  F Barkhof,et al.  MS Functional Composite , 2000, Neurology.

[13]  E. Cabanis,et al.  In vivo localized NMR proton spectroscopy of normal appearing white matter in patients with multiple sclerosis. , 1996, Journal of neuroradiology. Journal de neuroradiologie.

[14]  R. Knobler,et al.  A neurologic rating scale (NRS) for use in multiple sclerosis , 1984, Neurology.

[15]  A. Thompson,et al.  Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.

[16]  R. Tarducci,et al.  Localized 1H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis , 2002, Journal of Neurology.

[17]  G J Barker,et al.  Magnetisation transfer ratios and transverse magnetisation decay curves in optic neuritis: correlation with clinical findings and electrophysiology. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[18]  G. Comi,et al.  Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI , 2000, Neurology.

[19]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[20]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[21]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  P. Matthews,et al.  Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.

[23]  Jia Newcombe,et al.  High Resolution Proton NMR Spectroscopy of Multiple Sclerosis Lesions , 1995, Journal of neurochemistry.

[24]  Geoff J. M. Parker,et al.  1H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis , 1999, Journal of Neurology.

[25]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[26]  P. Matthews,et al.  Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.

[27]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[28]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[29]  A J Thompson,et al.  Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.

[30]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[31]  G. Fein,et al.  Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.

[32]  D. Gadian,et al.  Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis , 1991, The Lancet.

[33]  P M Matthews,et al.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.

[34]  R. Tarducci,et al.  Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. , 1999, Brain : a journal of neurology.

[35]  J. Valk,et al.  1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders , 1992, Annals of neurology.

[36]  C. Enzinger,et al.  Lower Levels of N-Acetylaspartate in Multiple Sclerosis Patients With the Apolipoprotein E ϵ4 Allele , 2003 .

[37]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[38]  P. Hecke,et al.  Human brain proton localized NMR spectroscopy in multiple sclerosis , 1991, Magnetic resonance in medicine.

[39]  Oded Gonen,et al.  Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. , 2002, AJNR. American journal of neuroradiology.

[40]  D. Goodkin,et al.  Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.

[41]  A. Thompson,et al.  Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis , 2002, Multiple sclerosis.

[42]  William H. Oldendorf,et al.  N-Acetyl-L-Aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain , 1989, Neuroscience & Biobehavioral Reviews.

[43]  G. Barker,et al.  1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.

[44]  P Kapeller,et al.  Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[45]  M. Cercignani,et al.  A QUANTITATIVE STUDY OF WATER DIFFUSION IN MS LESIONS AND NAWM USING ECHO-PLANAR IMAGING , 2000 .

[46]  E. Cabanis,et al.  Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis , 1999, Neurology.

[47]  P M Matthews,et al.  Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.

[48]  Christian Confavreux,et al.  Clinical outcomes assessment in multiple sclerosis , 1996, Annals of neurology.

[49]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[50]  R E Lenkinski,et al.  MR proton spectroscopy in multiple sclerosis. , 1992, AJNR. American journal of neuroradiology.

[51]  C. Mainero,et al.  Correlates of MS disability assessed in vivo using aggregates of MR quantities , 2001, Neurology.

[52]  F. Barkhof,et al.  Concurrent validity of the MS Functional Composite using MRI as a biological disease marker , 2001, Neurology.

[53]  Peter Kapeller,et al.  Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study , 2001, Journal of Neurology.

[54]  J S Wolinsky,et al.  Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.

[55]  G. Barker,et al.  Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis , 1999, Neurology.

[56]  M W Weiner,et al.  1H MRSI of normal appearing white matter in multiple sclerosis , 1997, Multiple sclerosis.

[57]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[58]  P. Christiansen,et al.  Early Time Course of JV-Acetylaspartate , Creatine and Phosphocreatine , and Compounds Containing Choline in the Brain After Acute Stroke , 2005 .

[59]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[60]  I. Wilkinson,et al.  Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. , 1993, Radiology.

[61]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[62]  S. Reingold,et al.  The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.

[63]  M Filippi,et al.  A Magnetization Transfer Imaging Study of Normal-Appearing White Matter in Multiple Sclerosis , 1995, Neurology.

[64]  M Cercignani,et al.  A quantitative study of water diffusion in multiple sclerosis lesions and normal-appearing white matter using echo-planar imaging. , 2000, Archives of neurology.

[65]  D. Gronwall.  Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion , 1977, Perceptual and motor skills.

[66]  P M Matthews,et al.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.

[67]  F Barkhof,et al.  Optimizing the association between disability and biological markers in MS , 2001, Neurology.

[68]  T. Olsen,et al.  Early Time Course of N‐Acetylaspartate, Creatine and Phosphocreatine, and Compounds Containing Choline in the Brain After Acute Stroke: A Proton Magnetic Resonance Spectroscopy Study , 1992, Stroke.

[69]  Jullie W Pan,et al.  Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T , 1996, Magnetic resonance in medicine.

[70]  F Barkhof,et al.  Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.

[71]  P. Matthews,et al.  Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.

[72]  D. Arnold,et al.  Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis , 2002, Journal of Neurology.

[73]  H. McFarland,et al.  Outcomes assessment in multiple sclerosis clinical trials: a critical analysis , 1995, Multiple sclerosis.

[74]  M Filippi,et al.  Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI , 1999, Neurology.